84 related articles for article (PubMed ID: 15025103)
1. Fibrinolysis and proteolysis in a cellular context.
Preissner KT; Machovich R
Thromb Haemost; 2004 Mar; 91(3):423-4. PubMed ID: 15025103
[No Abstract] [Full Text] [Related]
2. Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo.
Krishnamurti C; Alving BM
Semin Thromb Hemost; 1992 Jan; 18(1):67-80. PubMed ID: 1374195
[No Abstract] [Full Text] [Related]
3. Glycosylation influences the stability of human plasminogen activator inhibitor-1.
Van De Craen B; Declerck PJ; Gils A
Blood Coagul Fibrinolysis; 2012 Sep; 23(6):570-2. PubMed ID: 22874744
[No Abstract] [Full Text] [Related]
4. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activators and inhibitor type-1 in alveolar osteitis.
Serratì S; Margheri F; Bruschi S; D'Alessio S; Pucci M; Fibbi G; Tonelli P; Del Rosso M
Eur J Oral Sci; 2006 Dec; 114(6):500-3. PubMed ID: 17184232
[TBL] [Abstract][Full Text] [Related]
6. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
7. The role of the fibrinolytic system in corneal angiogenesis.
Vogten JM; Reijerkerk A; Meijers JC; Voest EE; Borel Rinkes IH; Gebbink MF
Angiogenesis; 2003; 6(4):311-6. PubMed ID: 15166500
[TBL] [Abstract][Full Text] [Related]
8. Fibronectin and regulation of proteolysis in cancer and tissue destruction.
Vaheri A; Salonen EM
Proc Finn Dent Soc; 1988; 84(1):13-8. PubMed ID: 2452437
[No Abstract] [Full Text] [Related]
9. Decreased peritoneal tissue plasminogen activator during prolonged laparoscopic surgery.
Brokelman WJ; Holmdahl L; Janssen IM; Falk P; Bergström M; Klinkenbijl JH; Reijnen MM
J Surg Res; 2009 Jan; 151(1):89-93. PubMed ID: 18541262
[TBL] [Abstract][Full Text] [Related]
10. Salmeterol enhances pulmonary fibrinolysis in healthy volunteers.
Maris NA; de Vos AF; Bresser P; van der Zee JS; Jansen HM; Levi M; van der Poll T
Crit Care Med; 2007 Jan; 35(1):57-63. PubMed ID: 17080003
[TBL] [Abstract][Full Text] [Related]
11. Tissue type plasminogen activator facilitates NMDA-receptor-mediated retinal apoptosis through an independent fibrinolytic cascade.
Kumada M; Niwa M; Hara A; Matsuno H; Mori H; Ueshima S; Matsuo O; Yamamoto T; Kozawa O
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1504-7. PubMed ID: 15790922
[TBL] [Abstract][Full Text] [Related]
12. Blood urokinase plasminogen activator system in chronic urticaria.
Kasperska-Zajac A; Brzoza Z; Rogala B
Arch Dermatol Res; 2007 Jan; 298(8):409-11. PubMed ID: 17102952
[TBL] [Abstract][Full Text] [Related]
13. Peritoneal fibrinolytic response to various aspects of laparoscopic surgery: a randomized trial.
Brokelman WJ; Holmdahl L; Bergström M; Falk P; Klinkenbijl JH; Reijnen MM
J Surg Res; 2006 Dec; 136(2):309-13. PubMed ID: 17054995
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro.
Tanaka A; Suzuki Y; Sugihara K; Kanayama N; Urano T
Life Sci; 2009 Jul; 85(5-6):220-5. PubMed ID: 19500599
[TBL] [Abstract][Full Text] [Related]
15. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
16. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
Nakamura R; Umemura K; Hashimmoto H; Urano T
Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
[TBL] [Abstract][Full Text] [Related]
17. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA
Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
[TBL] [Abstract][Full Text] [Related]
18. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
[TBL] [Abstract][Full Text] [Related]
19. Coagulation and fibrinolysis variables in pregnant women with type 1 diabetes mellitus.
Bronisz A; Rosc D; Bronisz M; Szymanski W; Junik R
Med Sci Monit; 2008 Nov; 14(11):CR574-9. PubMed ID: 18971874
[TBL] [Abstract][Full Text] [Related]
20. The urokinase system in patients with intermittent and persistent allergic rhinitis.
Kasperska-Zajac A; Brzoza Z; Rogala B
Blood Coagul Fibrinolysis; 2008 Oct; 19(7):685-8. PubMed ID: 18832910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
